Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

One of the most widely watched names in the healthcare sector is Hims & Hers Health Inc. (NYSE: HIMS), not only due to its ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

Novo Nordisk launched the partnership through CenterWell, Humana's (HUM) mail-order pharmacy, which would dispense the drugs prescribed by three telehealth providers — one of which was Hims & ...

Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy.

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk also accuses Hims & Hers of using misleading marketing practices that, it says, put patient safety at risk. "Based on Novo Nordisk's investigation, the 'semaglutide' active ...